The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy

European Journal of Heart Failure

Volumn 10, Issue 7, 2008, Pages 703-708

  McAlister, Finlay A ^a   Eurich, Dean T ^a   Majumdar, Sumit R ^a   Johnson, Jeffrey A ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Diabetes; Dose response relationship; Heart failure; Metformin; Sulfonylurea

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHLORPROPAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLIBENCLAMIDE; GLYCERYL TRINITRATE; METFORMIN; SULFONYLUREA; TOLBUTAMIDE;

ADULT; AGED; ARTICLE; CANADA; COHORT ANALYSIS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG MEGADOSE; FEMALE; HEART FAILURE; HIGH RISK POPULATION; HUMAN; INCIDENCE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT;

ADMINISTRATION, ORAL; AGED; DIABETES MELLITUS, TYPE 2; FEMALE; HEART FAILURE; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; MALE; METFORMIN; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK; SASKATCHEWAN; SULFONYLUREA COMPOUNDS;

EID: 46149094137     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejheart.2008.05.013     Document Type: Article

References (37)

1. Eurich D.T., McAlister F.A., Blackburn D.F., et al. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. BMJ 335 (2007) 497
2. Nichols G.A., Gullion C.M., Koro C.E., Ephross S.A., and Brown J.B. The incidence of congestive heart failure in type 2 diabetes. Diabetes Care 27 (2004) 1879-1884
3. Bertoni A.G., Hundley W.G., Massing M.W., et al. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care 27 3 (2004) 699-703
4. Dormandy J.A., et al., for the PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 (2005) 1279-1289
5. The DREAM (Diabetes Reduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368 (2006) 1096-1105
6. Karter A.J., Ahmed A.T., Liu J., Moffet H.H., and Parker M.M. Pioglitazone initiation and subsequent hospitalization for congestive heart failure. Diabetic Med 22 8 (2005) 986-993
7. Delea T.E., Edelsberg J.S., Hagiwara M., Oster G., and Phillips L.S. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. Diabetes Care 26 11 (2003) 2983-2989
8. Kahn S.E., et al., for the ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355 (2006) 2427-2443
9. Maru S., Koch G.G., Stender M., et al. Antidiabetic drugs and heart failure risk in patients with type 2 diabetes in the UK primary care setting. Diabetes Care 28 (2005) 20-26
10. Nichols G.A., Hillier T.A., Erbey J.R., and Brown J.B. Congestive heart failure in type 2 diabetes. Prevalence, incidence, and risk factors. Diabetes Care 24 (2001) 1614-1619
11. Hill A.B. The environment and disease: association or causation. Proc R Soc Med 58 (1965) 295-300
12. Johnson J.A., Majumdar S.R., Simpson S.H., and Toth E.L. Decreased mortality associated with metformin use compared to sulfonylurea monotherapy in type 2 diabetes mellitus. Diabetes Care 25 (2002) 2244-2248
13. Suissa S., Ernst P., Benayoun S., Baltzan M., and Cai B. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 343 5 (2000) 332-336
14. Goff Jr. D.C., Pandey D.K., Chan F.A., Ortiz C., and Nichaman M.Z. Congestive heart failure in the United States: is there more than meets the I(CD code)? The Corpus Christi Heart Project. Arch Intern Med 160 2 (2000) 197-202
15. McAlister F.A., Ghali W.A., Gong Y., Fang J., Armstrong P.W., and Tu J.V. Aspirin use and outcomes in a community-based cohort of 7352 patients discharged after first hospitalization for heart failure. Circulation 113 (2006) 2572-2578
16. Ray W.A. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 158 9 (2003) 915-920
17. Suissa S. Immortal time bias in pharmacoepidemiology. Am J Epidemiol 167 (2008) 492-499
18. Simpson S.H., Majumdar S.R., Tsuyuki R.T., Eurich D.T., and Johnson J.A. Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study. CMAJ 174 (2006) 169-174
19. Clark D.O., Von Korff M., Saunders K., Baluch W.M., and Simon G.E. A chronic disease score with empirically derived weights. Med Care 33 8 (1995) 783-795
20. Von Korff M., Wagner E.H., and Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 45 2 (1992) 197-203
21. Schneeweiss S., and Maclure M. Use of comorbidity scores for control of confounding in studies using administrative databases. Int J Epidemiol 29 5 (2000) 891-898
22. Thrainsdottir I.S., Aspelund T., Gudnason V., et al. Increasing glucose levels and BMI predict future heart failure. Experience from the Reykjavik Study. Eur J Heart Fail 9 (2007) 1051-1057
23. Stratton I.M., Adler A.I., Neil H.A.W., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321 (2000) 405-412
24. Iribrarren C., Karter A.J., Go A.S., et al. Glycemic control and heart failure among adult patients with diabetes. Circulation 103 (2001) 2668-2673
25. Barzilay J.I., Kronmal R.A., Gottdiener J.S., et al. The association of fasting glucose levels with congestive heart failure in diabetic adults 65 years: the Cardiovascular Health Study. J Am Coll Cardiol 43 (2004) 2236-2241
26. Held C., et al., for the ONTARGET/TRANSCEND Investigators. Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk. Circulation 115 (2007) 1371-1375
27. Fonarow G.C. Managing the patient with diabetes mellitus and heart failure: issues and considerations. Am J Med 116 (2004) 76S-88S
28. Howes L.G. Cardiovascular effects of sulphonylureas: role of K(ATP) channels. Diabetes Obes Metab 2 (2000) 67-73
29. Engler R.L., and Yellon D.M. Sulfonylurea KATP blockade in type II diabetes and preconditioning in cardiovascular disease. Time for reconsideration. Circulation 94 (1996) 2297-2301
30. Klepzig H., Kober G., Matter C., et al. Sulfonylureas and ischaemic preconditioning: a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. Eur Heart J 20 (1999) 439-446
31. Bell D.S.H. Secretagogues and cardiac risk. Endocrinologist 14 (2004) 33-37
32. Meier J.J., Gallwitz B., Schmidt W.E., Mugge A., and Nauck M.A. Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important?. Heart 90 (2004) 9-12
33. Masoudi F.A., Inzucchi S.E., Wang Y., Havranek E.P., Foody J.M., and Krumholz H.M. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure. An observational study. Circulation 111 (2005) 583-590
34. Eurich D.T., Majumdar S.R., McAlister F.A., Tsuyuki R.T., and Johnson J.A. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 28 (2005) 2345-2351
35. Jollis J.G., Simpson R.J., Cascio W.E., Chowdhury M.K., Crouse J.R., and Smith S.C. Relation between sulfonylurea therapy, complications, and outcome for elderly patients with acute myocardial infarction. Am Heart J 138 (1999) S376-S380
36. Meinert C.L., Knatterud G.L., Prout T.E., and Klimt C.R. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 19 (1970) 789-830 (Suppl)
37. UK Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853